65 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
Rubius Therapeutics Says To Highlight Programs At Platform And Pipeline Day In Q1 2022
Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell
SVB Leerink Maintains Market Perform on Rubius Therapeutics, Lowers Price Target to $14
SVB Leerink analyst Jonathan Chang maintains Rubius Therapeutics (NASDAQ:RUBY) with a Market Perform and lowers the price target from $20 to $14.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Rubius Therapeutics Reports Preclinical Data For RTX-224 Will Be Presented At Society For Immunotherapy Of Cancer Meeting Nov. 12 At 7 a.m. EST
Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell
Rubius Therapeutics Q2 EPS $(0.56) Misses $(0.49) Estimate
Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.49) by 14.29 percent. This is a 19.15 percent decrease over losses of $(0.47) per share
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Rubius Therapeutics Announces Publication Of RTX-240 Preclincal Data In Cancer Immunology, Immunotherapy
Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell
Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021
Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html
BeiGene (BGNE)